FIL Ltd Buys 65,984 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

FIL Ltd lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 48.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 201,376 shares of the medical device company's stock after buying an additional 65,984 shares during the period. FIL Ltd owned about 0.31% of Tandem Diabetes Care worth $7,254,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Baillie Gifford & Co. grew its stake in shares of Tandem Diabetes Care by 235.7% in the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after acquiring an additional 523,843 shares in the last quarter. GW&K Investment Management LLC grew its position in Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after purchasing an additional 323,674 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in Tandem Diabetes Care by 22.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company's stock valued at $56,040,000 after buying an additional 281,327 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Tandem Diabetes Care by 89.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 515,062 shares of the medical device company's stock worth $18,553,000 after buying an additional 242,965 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Tandem Diabetes Care by 397.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company's stock worth $11,121,000 after buying an additional 240,966 shares during the last quarter.

Wall Street Analysts Forecast Growth

TNDM has been the topic of a number of recent analyst reports. Morgan Stanley lowered Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Canaccord Genuity Group restated a "buy" rating and set a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and dropped their target price for the company from $35.00 to $24.00 in a research note on Tuesday, March 4th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $22.00 price target (down previously from $38.00) on shares of Tandem Diabetes Care in a research note on Monday, March 3rd. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.88.

Remove Ads

Tandem Diabetes Care Trading Up 0.1 %

Shares of Tandem Diabetes Care stock opened at $17.06 on Friday. The company's 50-day moving average price is $23.62 and its 200-day moving average price is $30.91. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -8.84 and a beta of 1.52.

Insider Buying and Selling

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos bought 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares in the company, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 2.20% of the stock is currently owned by insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.